Moreover, AOH1996 altered the tumor immune microenvironment into an inflamed state with increased CD8+ T-cell infiltration, rendering it a favorable partner for combination therapy with immune checkpoint inhibitors. The gene discussed is CD8A; the disease is neoplasm.